Introduction
============

Cocoa intake is related to a lower cardiovascular risk \[[@B1],[@B2]\]. Although, two recently published metaanalyses coincide that it is unclear whether cocoa consumption is related to reductions in adverse cardiovascular outcomes \[[@B3],[@B4]\].

The benefits of cocoa could be explained by an improved endothelial function and a beneficial effect on blood pressure \[[@B5]\], particularly in subjects with high levels of blood pressure \[[@B6]\]. However, the relationship of usual cocoa consumption to arterial stiffness parameters and central blood pressure is not clear \[[@B7],[@B8]\], although cocoa intake has been related to a lower prevalence of atherosclerotic plaques in carotid arteries \[[@B9],[@B10]\]. The relationship between cocoa consumption and arterial stiffness has only been studied in healthy individuals without cardiovascular risk factors.

The purpose of this study was to analyze the relationship of cocoa intake to central and peripheral blood pressure, arterial stiffness, and carotid intima-media thickness in subjects with some cardiovascular risk factor.

Methods
=======

A cross-sectional study conducted on 351 subjects in a primary care setting. Participants were recruited at primary care offices during 2010. Sample size was estimated to detect a minimum difference of 1 m/sec in pulse wave velocity (PWV) between two of the three groups in which sample was divided based on cocoa intake. Assuming an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test and a standard deviation of 2.1, 93 subjects per group were required, 279 in total. The study adhered to the principles of the Declaration of Helsinki \[[@B11]\], and was approved by an independent ethics committee of Salamanca University Hospital (Spain). Written informed consent to participate in the study was obtained from all subjects.

Information about the frequency of cocoa intake and all other foods was collected using the food frequency questionnaire of the University of Navarre, validated for Spain \[[@B12]\]. This questionnaire categorizes cocoa consumption as follows: Never, 1-3 servings/month, weekly, 2-4 servings/week, 5-6 servings/week, daily, 2-3 servings/day, 4-6 servings/day, more than 6 servings/day. Cocoa intake was determined as follows: the average daily consumption (weight) of cocoa-containing foods and beverages was multiplied by their individual percentage of cocoa contents, which were derived from food labels and from published data. Cocoa intake from individual foods was summed to yield the actual intake of cocoa in grams per day for each subject. We posteriorly divided the subjects according to estimated cocoa consumption. Low cocoa consumption was taken to represent the intake of ≤ 1 serving/week.

Procedures for measuring office and ambulatory blood pressure, ankle-brachial index (ABI), body mass index, and abdominal waist circumference have been reported in a prior publication \[[@B13]\].

Central blood pressure (CBP) and central and peripheral augmentation index (CAIx, PAIx) were estimated using the SphygmoCor System (AtCor Medical Pty Ltd., Head Office, West Ryde, Australia). With the patient sitting and the arm resting on a rigid surface, pulse wave in radial artery was tested and used to estimate the aortic pulse wave using a mathematic transformation. Inter-observer reliability was assessed before the start of the study using an intraclass correlation of 0.974 (95% CI: 0.936-0.989) in repeated measures in 22 subjects and with Bland-Altman analysis, where inter-observer agreement limits were 0.454 (95% CI: -9.876-10.785). Using the SphygmoCor System (Vx pulse wave velocity), PWV was measured with the patient in the supine position, estimating the delay in pulse wave at carotid and femoral level as compared to the electrocardiogram wave. Ambulatory arterial stiffness index (AASI) is defined as 1 minus the regression slope of 24-hour diastolic on systolic blood pressure \[[@B14]\].

Carotid ultrasonography to assess intima-media thickness of the common carotid artery (C-IMT) was performed by two investigators specifically trained for that purpose. A Sonosite Micromax ultrasound device (Sonosite Inc., Bothell, Washington, USA) paired with a 5-10 MHz multifrequency high-resolution linear transducer with Sonocal software was used for performing automatic measurements of IMT, in order to optimize reproducibility. Reliability of this measurement was evaluated before study start using intraclass correlation coefficient, which showed values of 0.974 (95% CI: 0.935-0.990) for intra-observer agreement on repeated measurements in 20 subjects, and 0.897 (95% CI: 0.740-0.959) for inter-observer agreement. Six measurements were taken on each carotid artery, using average values (average IMT) and maximum values (maximum IMT) calculated by the software automatically. Measurements were taken following the recommendations of the Manheim Carotid Intima-Media Thickness Consensus \[[@B15]\]. Cardiovascular risk was estimated using the SCORE \[[@B16]\] and D\'Agostino \[[@B17]\] equations.

Continuous variables are expressed as the mean ± standard deviation, and qualitative variables as frequency distributions. Association between qualitative variables was assessed using a Chi-square test, differences in means between groups with an ANOVA test, and a Scheffé test was used as a post hoc test with an alpha value \< 0.05. We used a multivariate analysis based on the ANCOVA method (analysis of covariance), to compare the arterial stiffness variables between different cocoa-intake groups using as adjustment variables age, gender, systolic blood pressure, diabetes and the presence of medical treatment (antihypertensive and lipid-lowering drugs). SPSS/PC + version 18.0 statistical software was used (SPSS Inc., Chicago, Illinois, USA).

Results
=======

Sample consisted of 351 subjects (mean age 54.76 years, 62.4% males). Mean cocoa consumption of the global sample was 4.30 ± 9.08 g/day, with an intake among those who consumed some cocoa of 7.74 ± 11.04 g/day, and a median value of 2 g/day. Table [1](#T1){ref-type="table"} shows the clinical and demographic characteristics of the population, as well as measures of arterial stiffness, central and peripheral blood pressure, C-IMT, and consumption of energy and immediate principles. Non-cocoa consumers had an older mean age and a lower 24-hour diastolic blood pressure as compared to the other groups, and also lower proportions of diabetic and dyslipidemic patients (*p*\< 0.05).

###### 

General demographic and clinical characteristics

  ----------------------------------------------------------------------------------------------------------
                                      Non-consumption\   Low consumption\    High consumption\    *p*
                                      (n = 156)          ≤ 1 serving/week\   \> 1 serving/week\   
                                                         (n = 106)           (n = 89)             
  ----------------------------------- ------------------ ------------------- -------------------- ----------
  Age                                 57.32 ± 11.10      54.11 ± 11.76       51.07 ± 11.57        \< 0.001

                                                                                                  

  Male (n, %)                         93 (59.60)         59 (55.70)          67 (75.30)           0.012

                                                                                                  

  Female (n,%)                        63 (40.40)         47(44.30)           22 (24.70)           \-

                                                                                                  

  Diabetes (n, %)                     58 (37.20)         23 (21.70)          8 (9.00)             \< 0.001

                                                                                                  

  Hypertension (n, %)                 126 (80.77)        83 (53.21)          64 (41.03)           0.273

                                                                                                  

  Obesity (BMI \> 30) (n, %)          58 (37.20)         36 (34.00)          20 (22.50)           0.057

                                                                                                  

  Dyslipidemia (n, %)                 109 (69.90)        84 (79.20)          75 (84.30)           0.034

                                                                                                  

  Smoking (n, %)                      35 (22.40)         27 (25.50)          23 (25.80)           0.783

                                                                                                  

  Antihypertensive drugs (n, %)       84 (53.80)         48 (45.30)          33 (37.10)           0.037

                                                                                                  

  Lipid lowering drugs (n, %)         59 (37.80)         27 (25.50)          14 (15.70)           0.001

                                                                                                  

  BMI (Kg/m^2^)                       28.78 ± 4.61       28.46 ± 4.31        27.50 ± 3.74         0.082

                                                                                                  

  Waist circumference (cm.)           98.21 ± 12.74      96.83 ± 11.44       95.93 ± 11.74        0.342

                                                                                                  

  Serum glucose (mg/dL)               106.12 ± 36.32     95.42 ± 25.89       89.52 ± 15.74        \< 0.001

                                                                                                  

  Total cholesterol (mg/dL)           200.29 ± 40.16     205.41 ± 35.33      206.07 ± 34.59       0.400

                                                                                                  

  Cardiovascular risk (Score)         5.08 ± 6.12        4.16 ± 7.06         2.82 ± 4.39          0.020

                                                                                                  

  Cardiovascular risk (D\'Agostino)   22.15 ± 15.60      18.68 ± 18.12       16.23 ± 13.66        0.017

                                                                                                  

  Office SBP (mmHg)                   138.81 ± 17.17     138.78 ± 17.86      140.12 ± 16.62       0.822

                                                                                                  

  Office DBP (mmHg)                   85.89 ± 10.74      87.09 ± 10.39       87.87 ± 11.27        0.357

                                                                                                  

  Peripheral pulse pressure (mmHg)    52.91 ± 13.00      51.68 ± 13.01       52.24 ± 11.45        0.736

                                                                                                  

  Central SBP (mmHg)                  131.66 ± 18.35     130.58 ± 17.26      132.17 ± 19.09       0.820

                                                                                                  

  Central DBP (mmHg)                  87.87 ± 11.50      88.05 ± 10.78       89.49 ± 11.73        0.534

                                                                                                  

  Central Pulse pressure (mmHg)       43.78 ± 14.12      42.53 ± 11.54       42.67 ± 12.76        0.696

                                                                                                  

  24 h SBP (mmHg)                     124.12 ± 12.48     125.73 ± 12.64      127.78 ± 12.39       0.087

                                                                                                  

  24 h DBP (mmHg)                     75.51 ± 9.52       77.47 ± 9.91        79.20 ± 9.35         0.014

                                                                                                  

  24 h Pulse pressure (mmHg)          48.60 ± 9.70       48.26 ± 9.12        48.58 ± 9.26         0.955

                                                                                                  

  PWV (m/s)                           9.22 ± 2.15        8.93 ± 2.41         8.47 ± 1.96          0.039

                                                                                                  

  C-IMT mean (mm.)                    0.74 ± 0.10        0.72 ± 0.11         0.71 ± 0.13          0.109

                                                                                                  

  C-IMT maximum (mm.)                 0.91 ± 0.12        0.89 ± 0.13         0.88 ± 0.16          0.100

                                                                                                  

  CAIx                                30.24 ± 11.25      30.84 ± 11.34       28.81 ± 11.11        0.439

                                                                                                  

  PAIx                                94.74 ± 22.91      92.03 ± 17.95       88.43 ± 21.39        0.085

                                                                                                  

  AASI                                0.38 ± 0.06        0.37 ± 0.05         0.37 ± 0.05          0.331

                                                                                                  

  Day AASI                            0.38 ± 0.06        0.37 ± 0.05         0.37 ± 0.05          0.363

                                                                                                  

  Night AASI                          0.39 ± 0.14        0.37 ± 0.16         0.39 ± 0.16          0.786

                                                                                                  

  ABI                                 1.07 ± 0.10        1.08 ± 0.11         1.08 ± 0.09          0.791

                                                                                                  

  Total energy (Kcal/day)             2312.80 ± 691.41   2487.15 ± 660.39    2907.62 ± 777.29     \< 0.001

                                                                                                  

  Carbohydrates (g/day)               259.47 ± 95.26     269.97 ± 82.01      323.36 ± 99.28       \< 0.001

                                                                                                  

  Protein (g/day)                     101.87 ± 32.40     108.73 ± 30.33      113.29 ± 28.44       0.016

                                                                                                  

  Total fat (g/day)                   87.35 ± 31.93      99.60 ± 36.93       120.11 ± 37.92       \< 0.001
  ----------------------------------------------------------------------------------------------------------

BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, IMT: Intima-media thickness, PWV: Pulse wave velocity, C-IMT: Carotid intima-media thickness, CAIx: Central augmentation index, PAIx: Peripheral augmentation index, AASI: Ambulatory arterial stiffness index, ABI: ankle-brachial index

Data for qualitative variables are expressed as n (%) and quantitative variables as mean ± standard deviation

*p*: statistically significant differences (*p*\< 0.05)

The proportion of patients treated with drugs was greater among the non-consumers of cocoa than in the high consumption group, referred to both the antihypertensive agents (53.80% vs 37.80%) and the lipid-lowering drugs (37.10% vs 15.70%). A higher proportion of males (30.59%) as compared to females (16.67%) reported high cocoa consumption.

PWV showed a significant difference between the non-consumers (9.22 m/sec) and the high consumption group (8.47 m/sec) (*p*= 0.039). However, in the multivariate analysis, on adjusting for age, gender, the presence of diabetes, systolic blood pressure and antihypertensive and lipid-lowering drug use, this difference disappeared. The power of the contrast was 81% for detecting differences in PWV between high consumers and non-consumers, and 42% between high consumers and low consumers. All other arterial stiffness measures showed no differences between the different consumption groups (Figure [1](#F1){ref-type="fig"}).

![**Multivariate analysis (ANCOVA)**. Box plots of PWV, AASI, C-IMT, and PAIx in the different cocoa consumption groups. Mean (95% CI) adjusted for age, gender, the presence of diabetes, systolic blood pressure and antihypertensive and lipid-lowering drug use.](1475-2891-11-8-1){#F1}

We re-analyzed the data, excluding the diabetics, without any modification of the results or conclusions obtained.

Discussion
==========

Although there was a trend to a decreased arterial stiffness as cocoa consumption increased, data collected show that cocoa intake had no influence on arterial stiffness or C-IMT measurements, or on central and peripheral blood pressure values, in subjects with some cardiovascular risk factors.

Vlachopoulos et al. \[[@B7]\], found that regular cocoa intake is related to decreased aortic stiffness and improved central hemodynamics. In their study population, the mean cocoa intake in healthy individuals was 4.63 g/day. Similar amount in terms of cocoa-intake to those obtained in our study (4.30 g /day). The inconsistency between this study and our findings merits comments. While subjects in the previous trial were healthy, our study included subjects with some cardiovascular risk factor (hypertension, diabetes, or dyslipidemia). These risk factors can influence the measures used to estimate arterial stiffness. In addition, many of the patients were receiving antihypertensive medication and lipid-lowering drugs, which may influence the results obtained. However, the interest of the study is that no previous evaluations have been made of the relationship between cocoa consumption and arterial stiffness in subjects of this kind.

However, data found in our population were similar to those collected by Ried K et al. \[[@B6]\], who concluded that cocoa was superior to placebo for reducing blood pressure in prehypertension. In the van den Bogaard B et al. study \[[@B8]\], cocoa increased 24-hour mean blood pressure and PWV, but decreased central systolic blood pressure and augmentation index. Thus, these authors did not also find a consistent relationship between cocoa intake and blood pressure and arterial stiffness measurements.

Djousse L and Lewis JR \[[@B9],[@B10]\], recorded a inversely association between cocoa consumption and carotid atherosclerotic plaque prevalence. However, in coincidence of our study, no significant relationship was found between C-IMT and cocoa intake. There are several possible explanations for this results. In our study, the three groups of cocoa-intake are very heterogenous with differences in age, gender and the proportion of subjects with antihypertensive and lipid-lowering drugs. This fact may influence the results.

A limitation of the study is the statistical power because may not be sufficient to detect differences between cocoa-intake groups that could really exist in the population.

Conclusions
===========

In conclusion, in subjects with some cardiovascular risk factors, cocoa consumption does not imply improvement in the arterial stiffness values. However, further studies specifically designed to test the relationship are needed.
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